Discussions See our regular blog for helpful information on the payer markets! Is It That Trump Fails Again to Understand the Problem? The Premium Pricing Problem for New Product Launches Risk-Adjustment Payments May Come at the Expense of the GOP The Pitfalls of Pinning Savings on Biosimilars The Value Mirage: Will Allowing Health Plans to Sell Across State Lines Lower Premiums? Are 2 Biosimilars to the Same Originator Product Biosimilar to Each Other? Market Access, Sales Training, and the Mock P&T Biosimilars, Coverage Decision Making, and Getting the Answers You Need What a Mock P&T Committee Is and What It Is not The Technology Assessment Committee: Coverage Decision Making for the Medical Benefit Decision Making on Specialty Pharmaceuticals: P&T Committee, Technology Assessment Committee, or Something New? The 5 Critical Features of an Excellent Payer Market Research Network Demonstrating Specialty Pharmaceutical Value and an Opportunity to Meet the Challenge Social Context and Payer Market Research Biosimilars Looming on the Horizon: How Will Payers React? Biosimilars: A Day of Reckoning Has Arrived A Postmarketing Surveillance Effort for New Biosimilars What Will Be the Single Greatest Change in Paying for Biopharmaceuticals Over the Next 5 Years? Which Types of Questions Cannot Be Answered by Payer Market Research? Pharmaceutical Pricing: Real Value vs. Revenue Forecasting Biosimilar Launches: Ready, Set, Not-so-Fast!